healio.com

48 articles in the TruthFoundry index. Each links out to the original.

• Bezisterim reduces long COVID symptoms in phase 2 clinical trial · Phase 2 trial finds Bezisterim improves fatigue and cognitive symptoms for long COVID patients.
• FDA approves Zilbrysq autoinjector for generalized myasthenia gravis · US FDA approved UCB's Zilbrysq autoinjector for adult generalized myasthenia gravis patients.
• Meta-analysis finds underreported migraine and endometriosis overlap · Study of 13 million women finds endometriosis patients are 2.3x more likely to have migraine.
• Ophthalmologist shares ergonomic habits to prevent career-ending injuries · Dr. Sumit Garg advises physicians to maintain ergonomic awareness throughout their week to prevent long-term physical strain.
• Enzyme-Inducing Antiseizure Drugs Linked to 51% Higher Bone Disease Risk · A study finds enzyme-inducing antiseizure medications increase osteoporosis risk by 51% while vitamin D supplementation remains low.
• FDA Approves Enspryng As First At-Home Thyroid Eye Disease Treatment · FDA approved Genentech's Enspryng as first at-home subcutaneous thyroid eye disease treatment.
• ADHD Linked to Higher Dementia Risk in Older Adults · Study finds ADHD associated with four-fold higher risk of cognitive impairment in people aged 50 and older.
• Physical Activity Slows Cognitive and Motor Decline in Parkinson's Disease · Higher physical activity levels are linked to slower cognitive and motor decline in Parkinson's disease patients.
• Rainwater Foundation awards $3M for tauopathy research · The Rainwater Charitable Foundation awarded $3 million to four researchers to study tau protein mechanisms in neurodegenerative diseases.
• Rexaceract Stabilizes Parkinson's Motor Symptoms Over 360 Days in Phase 1b Study · Gain Therapeutics reports stable motor scores and good tolerability for Parkinson's drug rexaceract after 360 days.
• Study finds epilepsy drugs may reduce hormonal contraceptive effectiveness · One third of child-bearing epilepsy patients face contraceptive interaction risk.
• Nobel Prize Awarded to Three Optogenetics Researchers · Karl Deisseroth, Peter Hegemann, and Georg Nagel receive Nobel Prize for pioneering optogenetics research.
• SurVaxM glioblastoma vaccine trial misses endpoint, benefits younger patients · Phase 2B SurVaxM trial failed overall survival endpoint but benefited patients aged 65 or younger.
• High-Level Military Blast Exposure Linked to Chronic Health Conditions in Veterans · Research links self-reported high-level blast exposure in veterans to increased risks of seizures, neuropathy, and cardiovascular diseases.
• Study links frequent cannabis use to increased epilepsy severity · Published research finds frequent cannabis use correlates with greater drug-resistant epilepsy burden.
• FDA Approves Tavapadon (Juvmo) for Parkinson's Disease · AbbVie's tavapadon becomes the first FDA-approved Parkinson's treatment targeting D1/D5 receptors.
• FDA grants orphan drug status to Qivigy for stiff person syndrome · FDA grants orphan drug designation to Qivigy for potential stiff person syndrome treatment
• Women's Medical School Gains Fail to Translate to Clinical Trial Leadership · Despite rising enrollment, women hold only one-third of clinical trial principal investigator roles.
• FDA Approves Juvmo, First D1/D5 Dopamine Agonist for Parkinson's Disease · The FDA approved Juvmo (tavapadon), a once-daily D1/D5 receptor agonist for adults with Parkinson's disease.
• Multi-fraction Radiation Improves Control for Large Brain Metastases · A randomized trial found multi-fraction stereotactic radiation improved local control and survival for large resected brain metastases.
• Art Exhibition at 2026 European Epilepsy Congress Challenges Clinical Stigma · UCB-organized art exhibit at the 2026 European Epilepsy Congress aims to humanize epilepsy through three artists' works.
• CDC awards $1.6M grant for updated US pediatric epilepsy prevalence research · Weill Cornell researchers receive CDC funding to study US pediatric epilepsy prevalence using AI.
• B-cell therapies reduce MS relapses and lesions but not disability after two years · B-cell depleting therapies reduced MS relapses and lesions compared to oral treatments, but disability scores remained unchanged after two years.
• AbbVie's Atogepant Reduces Menstrual Migraine Days in Phase 3 Trial · AbbVie reports atogepant significantly reduced menstrual migraine days compared to placebo in the Phase 3 LUNA study.
• Severe Asthma Linked to Brain Structure Changes in New Study · Severe type 2 asthma is associated with reduced brain volume and disrupted white matter integrity compared to mild cases.
• FDA approves Isembyld, first muscle-targeted SMA treatment · The FDA approved Isembyld, the first therapy to improve motor function in spinal muscular atrophy patients by targeting muscle.
• Ophthalmologists most accurate at referring for thyroid eye disease, study finds · Ophthalmologists had the highest accuracy (91.9%) in referring for thyroid eye disease, according to a retrospective study.
• Q&A: Parkinson's burden expected to rise; exercise, policy can help mitigate · Zoltan Mari says Parkinson's costs are rising in Europe and the US; exercise should be core treatment.
• FDA approves Zanvastro, first disease-modifying treatment for Alexander disease · FDA approves Ionis's Zanvastro as first disease-modifying treatment for Alexander disease, priced at $285,000 per dose.
• Veterans with Melanoma Face Higher Parkinson's Disease Risk · A study finds veterans with melanoma have a 47% higher risk of developing Parkinson's disease.